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The economic impact of rheumatic heart disease in 
developing countries
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Abstract 
Background Rheumatic heart disease (RHD) is a neglected disease of poverty that is the most common paediatric 
cardiovascular condition in developing countries. Most RHD deaths occur in children and working-age adults, 
in whom the economic impact of premature death is high. Despite RHD being a preventable disease, global research 
and development funding for RHD was recently estimated at US$1·7 million, or about 0·1% of all global health 
funding. Decisions to scale up costly medical and surgical interventions for RHD are hindered, in part, by lack 
of evidence for the so-called return on investment that could be achieved through prevention of RHD-related mortality. 
We conducted a modelling study using data from 107 countries to estimate the economic impact of excess mortality 
from RHD.
Methods We used the full income approach to quantify the economic losses from RHD in 107 countries where the 
disease is endemic during 2010. Our analysis synthesised data from the Global Burden of Disease 2010 study, WHO 
life tables, UN population estimates, and World Bank macroeconomic indicators such as gross domestic product 
(GDP) per capita that are used in full-income calculations. We used the RHD mortality pattern in Costa Rica in 2010 
as a baseline from which to deﬁ ne excess mortality. Data from this country were used because of Costa Rica’s 
demonstrated success in controlling RHD in previous decades as well as its health system’s resilience under political 
and economic constraints. We reported costs discounted at 3% yearly as well as undiscounted.
Findings We noted that the cost of the approximately 222 000 excess deaths from RHD in 2010 was around 
US$ (2014) 2·2 trillion (discounted) or US$5·4 trillion (undiscounted). Most of the economic burden of RHD was in 
countries with large populations in south Asia and east Asia. Our estimates were roughly proportional to those reported 
in a full-income study of HIV/AIDS mortality in sub-Saharan Africa, although our estimates were 10–100 times higher 
than those obtained using other economic methods, such as multiples of GDP per capita per disability-adjusted life-
year. 
Interpretation RHD continues to exert massive economic eﬀ ects globally, mainly because of premature death 
in children and working-age adults. The economic cost of RHD in developing countries is over a million times higher 
than current donor funding levels. Our estimates suggest that careful increases in public-sector and private-sector 
spending on eﬀ ective RHD prevention and control measures could provide impressive returns on investment. Future 
work will compare the full-income results to other economic evaluation methods such as those recommended by the 
Commission on Macroeconomics and Health. Our results could be the basis for beneﬁ t-cost analyses of medical and 
surgical interventions in resource-limited countries.
Funding None.
Copyright © Watkins et al. Open Access article distributed under the terms of CC BY.
Declaration of interests
We declare no competing interests. 
Published Online
March 26, 2015
University of Washington, 
Seattle, WA, USA 
(D Watkins MD); and Global 
Heart Network Foundation, 
San Francisco, CA, USA 
(A Daskalakis BS)
Correspondence to: 
Dr David A Watkins, Division 
of General Internal Medicine, 
University of Washington, 
Seattle, WA, USA.
davidaw@uw.edu
